The chances of former shareholders in Celgene missing out on the big pay-out from their contingent value right (CVR) deal with Bristol-Myers Squibb have risen sharply, after the FDA refused to accept ...
Airflow 2's April 2026 death warrant is signed; either embrace the "Asset" revolution now or get left behind with a broken UI and obsolete dependencies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results